EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis

Anja Tiede, Lena Stockhoff, Zhaoli Liu, Hannah Rieland, Jim B Mauz, Valerie Ohlendorf, Birgit Bremer, Jennifer Witt, Anke Kraft, Markus Cornberg, Jan B Hinrichs, Bernhard C Meyer und 4 weitere

Clinical and Molecular Hepatology · 2025

DOI: 10.3350/cmh.2024.0587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Anja Tiede und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Portasystemic Shunt, Transjugular Intrahepatic, Liver Cirrhosis, Inflammation. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Hannover Medical School, Elser-Kröner-Fresenius-Stiftung, MHHplus foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Systemic Inflammation (SI) is considered a key mechanism in disease progression and development of complications in decompensated liver cirrhosis. SI is mainly driven by portal hypertension and bacterial translocation. Transjugular intrahepatic portosystemic shunt (TIPS) insertion represents an effective treatment for portal hypertension. This study aims to investigate the impact of TIPS insertion on SI and bacterial translocation.

Methods

We prospectively included 59 cirrhotic patients undergoing TIPS insertion. Blood samples were collected at TIPS insertion and follow-up (FU) 1, 3, 6, and 12 months thereafter. At all time points, we performed a comprehensive analysis of SI including 43 soluble inflammatory markers (SIMs), and surrogates of bacterial translocation (sCD14, sCD163). To investigate long-term kinetics of SI, C-reactive protein (CRP) and white blood cells (WBC) were retrospectively analyzed in a cohort of 177 patients up to 3 years after TIPS insertion.

Results

At TIPS insertion, 30/43 SIMs, sCD14, and sCD163 measured significantly higher in cirrhotic patients compared to healthy controls. By FU6 25 SIMs and sCD14 measured at significantly lower levels compared to baseline. Interestingly, in patients with TIPS indication of refractory ascites, IL-6 decreased to levels documented in earlier stages of cirrhosis. In long-term follow-up, CRP levels significantly decreased after TIPS insertion, which translated into lower mortality in Cox regression analysis (HR 0.968, p=0.042). Notably, patients with residual ascites post-TIPS showed significantly higher CRP and IL-6 levels across all follow-ups compared to patients with resolved ascites.

Conclusions

Decreasing portal hypertension via TIPS insertion leads to a significant attenuation of SI and bacterial translocation over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Portasystemic Shunt, Transjugular IntrahepaticLiver CirrhosisInflammationHumansMaleFemaleMiddle AgedC-Reactive ProteinAgedHypertension, PortalProspective StudiesBiomarkersCD163 AntigenBacterial TranslocationLipopolysaccharide ReceptorsAntigens, CDAntigens, Differentiation, MyelomonocyticReceptors, Cell SurfaceRetrospective StudiesAdultLeukocyte Count

Stichwörter der Autor:innen

Bacterial translocationLiver cirrhosisPortal hypertensionSystemic inflammationTransjugular intrahepatic portosystemic shunt insertion

Substanzen

C-Reactive ProteinBiomarkersCD163 AntigenLipopolysaccharide ReceptorsAntigens, CDAntigens, Differentiation, MyelomonocyticReceptors, Cell Surface

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
  • German Center for Infection Research (DZIF), Hannover-Braunschweig, Germany.
  • Niels-Stensen-Kliniken Marienhospital, Osnabrück, Germany.
  • Center for Individualized Infection Medicine (CiiM), a joint venture between the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH), Hannover, Germany.
  • TWINCORE, Centre for Experimental and Clinical Infection Research, a Joint Venture Between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
  • Cluster of Excellence RESIST (EXC2155), Hannover Medical School, Hannover, Germany.

Förderung

  • Hannover Medical School
  • Elser-Kröner-Fresenius-Stiftung
  • MHHplus foundation

Zitieren

APA

Tiede, A., Stockhoff, L., Liu, Z., Rieland, H., Mauz, J. B., Ohlendorf, V., Bremer, B., Witt, J., Kraft, A., Cornberg, M., Hinrichs, J. B., Meyer, B. C., Wedemeyer, H., Xu, C. J., Falk, C. S., & Maasoumy, B. (2025). Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0587

Vancouver

Tiede A, Stockhoff L, Liu Z, Rieland H, Mauz JB, Ohlendorf V, et al. Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0587

BibTeX
@article{Tiede2025,
  author = {Tiede, Anja and Stockhoff, Lena and Liu, Zhaoli and Rieland, Hannah and Mauz, Jim B and Ohlendorf, Valerie and Bremer, Birgit and Witt, Jennifer and Kraft, Anke and Cornberg, Markus and Hinrichs, Jan B and Meyer, Bernhard C and Wedemeyer, Heiner and Xu, Cheng-Jian and Falk, Christine S and Maasoumy, Benjamin},
  title = {Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  doi = {10.3350/cmh.2024.0587}
}
Kostenlos starten →